Abbott Laboratories (ABT) Accounts Payables (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Accounts Payables data on file, last reported at $4.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 11.03% year-over-year to $4.7 billion; the trailing twelve-month figure through Mar 2026 stood at $4.7 billion (up 11.03% YoY), and the FY2025 full-year result was $4.2 billion, up 1.07% from the prior year.
• Accounts Payables advanced to $4.7 billion in Q1 2026, from $4.2 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.8 billion in Q1 2022 to a low of $4.0 billion in Q3 2023.
• A 5-year average of $4.3 billion and a median of $4.2 billion in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables rose 16.99% in 2022 and retreated 12.4% in 2023, its largest moves.
• Tracing ABT's Accounts Payables over 5 years: stood at $4.6 billion in 2022, then decreased by 6.77% to $4.3 billion in 2023, then retreated by 2.33% to $4.2 billion in 2024, then advanced by 1.07% to $4.2 billion in 2025, then grew by 10.35% to $4.7 billion in 2026.
• Business Quant data shows ABT's Accounts Payables at $4.7 billion in Q1 2026, $4.2 billion in Q4 2025, and $4.1 billion in Q3 2025.